heed the advice when all the good news are out , time to sell aggressively n buy back when it is back to normal . Retracement is imminent looking by the oversold position.
Hovid Bhd - Back in the pink of health We think that investors may have overlooked the potential of Hovid’s pharmaceutical business and efforts to register tocotrienols (a type of Vitamin E) as a US FDA-approved drug. These positives also appear to be eclipsed by losses at its Carotech subsidiary over the past few years. FY6/13 net profit was the best since FY07 while revenue ex-Carotech hit a record high. Hovid is well positioned to tap the growing healthcare spending in Malaysia and other emerging economies. This, plus its defensive earnings, suggests that Hovid should be worth RM0.43 conservatively, based on 16.5x CY15 P/E, a 10% discount to the healthcare sector’s 1-year average forward P/E. This suggests 39% share price upside.
Hovid as brighter future - Read more: Joining hands to fight stroke
Janet Yeo (fourth from right) with representatives from Ara Damansara Medical Centre, Hovid Bhd, Yee Lee Trading and Caring Pharmacy Retail Management Sdn Bhd at the launch of the National Stroke Campaign.
Posted by Alex Leow Sze Shen > Oct 23, 2013 09:27 AM | Report Abuse
Retracing now!
No Alex, sharks pushing down with 10 to 30 lots to collect cheaper....refer back please. Confident it will go high reaching it's TP of 43 cents, so hold and panic not.
Alex Leow Sze Shen lee9fold: yes, I am still holding it! Confident it will break 0.38 soon! 23/10/2013 22:47
good for u brother Alex, let's prosper more together. I am also confident that there's more to come. Remember yesterday the sharks are pushing down with 1 to 30 lots continuously and there's nothing much to panic about. Yesterday, profit takers may have added to the selling too but down only half a cent. Let's hope Hovid gets more momentum today and reaching new heights. Cheers & good luck to all too.
Posted by Alex Leow Sze Shen > Oct 24, 2013 12:09 AM | Report Abuse
But also bear in mind that director David Ho is selling the shares as well, this gives an impact but I think not serious though
Couldn't agree more with you brother Alex. Yes David Ho sold 2,702,100 shares but he still has 292,776,400 shares, so it's only a very small percentage of his holdings that he sold, so it just another normal transaction & nothing too worrying.
Cheers brother Alex & you have a great day too, good luck to you too brother....all the best.
come on... be objective.. company owner won't simply sell their shares.. So David Ho sale of Hovid share may be an indicator that the share price almost near its peak at least in the short term
- Handsome gain of 38%. Since our initial Trading Buy recommendation on Hovid Bhd (HOVID) at RM0.25 on 8-Nov-2012, the stock has performed very well with 38% appreciation. Note that HOVID share price has outperformed the FBMKLCI’s gain of 10% during the same timeline.
- FY13 earnings grew by 30% but this should have already been priced in. Note that HOVID’s FY13 net profit increased by 30% YoY to RM20.3m which was within our expectation. The earnings growth is due to 18% earnings growth in its pharmaceutical division and the exclusion of Carotech’s losses from FY13 onwards. Overall, we think that the current share price increase of 38% has already priced in the strong earnings growth. Looking ahead into FY14, we think earnings growth could slow down to 23% YoY as due to higher earnings base but it will still deliver a decent set of net profit of RM25m in FY14 due to capacity expansion.
- Take profit for now. HOVID’s valuation of 11.8x FY14E Fwd. PE appears to be slightly stretched at this juncture as compared to FBM Small Cap FY14E Fwd. PE of 9.3x. We value HOVID at RM0.365 by applying 11.1x Fwd. PE. to its FY14E EPS of 3.29 sen. Our 11.1x Fwd. PE is based on 1-year historical PER as the previous data before FY13 incorporate Carotech losses which we think do not reflect current HOVID business structure. Overall, share price upside appears to be minimal.
- But it is still a good long-term investment. Despite our Take Profit recommendation, HOVID long-term prospect remains intact as the Group is actively looking for opportunities in new overseas markets. Its emphasis in research and development (R&D) may also result in higher-margin products in the long run on better pricing power.
SWOT ANALYSIS
- Strength: Continuous input on R&D, rich products portfolio and extensive international network.
- Weaknesses: Potential margin squeeze due to competition.
- Opportunities: Further growth in its extensive international distribution network particularly in healthcare products in developing countries. Introduction of more generic drugs.
- Threats: Slower than expected drugs registration approval.
TECHNICALS
- Resistance: RM0.360 (R1), RM0.390 (R2)
- Support: RM0.340 (S1), RM0.320 (S2)
- Comments: The share price has started to pull back after the recent impressive run, judging from the overbought conditions in key indicators such as RSI and Stochastic. As a result, for short-term trading purpose, we believe this is good time to take some profit off the table.
BUSINESS OVERVIEW
Hovid Berhad (Bursa Code: 7213, HOVID) is engaged in the manufacturing of pharmaceutical and herbal products. The company is a pharmaceutical manufacturer of medicinal preparations and health supplements with more than 300 products distributed over 50 countries globally. Hovid's products include antibiotics, antidiabetics, antihypertensives, antimalarial and anti-inflammatory analgesics ranging from skin care and hair care to health beverages. Its products are manufactured in GMP compliant plants. The group’s popular products include Tocovid SupraBio and Ho Yan Hor Herbal Tea.
BUSINESS SEGMENTS
Hovid’s core business is its Pharmaceutical segment, which is involved in the manufacturing and sale of pharmaceutical products.
Technical wise seems to have retracement. See whether support can hold. Seems to be a lot of sellers today for wb but price didn't move that much. Tomorrow is anoth er day. Big up or big down?...
ameen007: yes, definately will have retracement after big uptrend! Now research house calling to take profit but despite heavy sellers, but price still maintain!
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
leslieroycarter
5,777 posts
Posted by leslieroycarter > 2013-10-22 12:25 | Report Abuse
heed the advice when all the good news are out , time to sell aggressively n buy back when it is back to normal . Retracement is imminent looking by the oversold position.